Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
23
ALBBY Quote, Financials, Valuation and Earnings
Last price:
$13.14
Seasonality move
:
7.73%
Day range:
$13.14 - $13.14
52-week range:
$7.72 - $19.45
Dividend yield:
0%
P/E ratio:
39.73x
P/S ratio:
2.32x
P/B ratio:
4.48x
Volume:
16
Avg. volume:
167
1-year change:
46.33%
Market cap:
$10.6B
Revenue:
$4.2B
EPS (TTM):
$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALBBY
Alibaba Health Information Technology Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.58 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$26M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALBBY
Alibaba Health Information Technology Ltd.
|
$13.14 | -- | $10.6B | 39.73x | $0.00 | 0% | 2.32x |
|
HCM
HUTCHMED (China) Ltd.
|
$13.52 | $22.58 | $2.3B | 5.04x | $0.00 | 0% | 3.91x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
$0.75 | -- | $8.2M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$16.91 | $26.00 | $284.6M | -- | $0.00 | 0% | 3.29x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$24.60 | -- | $12.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALBBY
Alibaba Health Information Technology Ltd.
|
-- | 0.792 | -- | 2.22x |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.509 | -- | 4.41x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 4.220 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 21.200 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALBBY
Alibaba Health Information Technology Ltd.
|
-- | -- | 9.22% | 9.22% | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
Alibaba Health Information Technology Ltd. vs. Competitors
-
Which has Higher Returns ALBBY or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Alibaba Health Information Technology Ltd.'s net margin of --. Alibaba Health Information Technology Ltd.'s return on equity of 9.22% beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital ALBBYAlibaba Health Information Technology Ltd.-- -- $2.2B HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About ALBBY or HCM?
Alibaba Health Information Technology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.58 which suggests that it could grow by 67.05%. Given that HUTCHMED (China) Ltd. has higher upside potential than Alibaba Health Information Technology Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Alibaba Health Information Technology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ALBBYAlibaba Health Information Technology Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is ALBBY or HCM More Risky?
Alibaba Health Information Technology Ltd. has a beta of 1.029, which suggesting that the stock is 2.862% more volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.402%.
-
Which is a Better Dividend Stock ALBBY or HCM?
Alibaba Health Information Technology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alibaba Health Information Technology Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALBBY or HCM?
Alibaba Health Information Technology Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Alibaba Health Information Technology Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Alibaba Health Information Technology Ltd.'s price-to-earnings ratio is 39.73x while HUTCHMED (China) Ltd.'s PE ratio is 5.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alibaba Health Information Technology Ltd. is 2.32x versus 3.91x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALBBYAlibaba Health Information Technology Ltd.2.32x 39.73x -- -- HCMHUTCHMED (China) Ltd.3.91x 5.04x -- --
-
Which has Higher Returns ALBBY or HKPD?
Hong Kong Pharma Digital Technology Holdings Ltd. has a net margin of -- compared to Alibaba Health Information Technology Ltd.'s net margin of --. Alibaba Health Information Technology Ltd.'s return on equity of 9.22% beat Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALBBYAlibaba Health Information Technology Ltd.-- -- $2.2B HKPDHong Kong Pharma Digital Technology Holdings Ltd.-- -- -- -
What do Analysts Say About ALBBY or HKPD?
Alibaba Health Information Technology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Alibaba Health Information Technology Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe Alibaba Health Information Technology Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ALBBYAlibaba Health Information Technology Ltd.0 0 0 HKPDHong Kong Pharma Digital Technology Holdings Ltd.0 0 0 -
Is ALBBY or HKPD More Risky?
Alibaba Health Information Technology Ltd. has a beta of 1.029, which suggesting that the stock is 2.862% more volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALBBY or HKPD?
Alibaba Health Information Technology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alibaba Health Information Technology Ltd. pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALBBY or HKPD?
Alibaba Health Information Technology Ltd. quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues of --. Alibaba Health Information Technology Ltd.'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of --. Notably, Alibaba Health Information Technology Ltd.'s price-to-earnings ratio is 39.73x while Hong Kong Pharma Digital Technology Holdings Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alibaba Health Information Technology Ltd. is 2.32x versus 0.75x for Hong Kong Pharma Digital Technology Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALBBYAlibaba Health Information Technology Ltd.2.32x 39.73x -- -- HKPDHong Kong Pharma Digital Technology Holdings Ltd.0.75x 8.18x -- --
-
Which has Higher Returns ALBBY or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Alibaba Health Information Technology Ltd.'s net margin of -28.82%. Alibaba Health Information Technology Ltd.'s return on equity of 9.22% beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital ALBBYAlibaba Health Information Technology Ltd.-- -- $2.2B PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About ALBBY or PRE?
Alibaba Health Information Technology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 83.32%. Given that Prenetics Global Ltd. has higher upside potential than Alibaba Health Information Technology Ltd., analysts believe Prenetics Global Ltd. is more attractive than Alibaba Health Information Technology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ALBBYAlibaba Health Information Technology Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is ALBBY or PRE More Risky?
Alibaba Health Information Technology Ltd. has a beta of 1.029, which suggesting that the stock is 2.862% more volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALBBY or PRE?
Alibaba Health Information Technology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alibaba Health Information Technology Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALBBY or PRE?
Alibaba Health Information Technology Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Alibaba Health Information Technology Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Alibaba Health Information Technology Ltd.'s price-to-earnings ratio is 39.73x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alibaba Health Information Technology Ltd. is 2.32x versus 3.29x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALBBYAlibaba Health Information Technology Ltd.2.32x 39.73x -- -- PREPrenetics Global Ltd.3.29x -- $23.6M -$6.8M
-
Which has Higher Returns ALBBY or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Alibaba Health Information Technology Ltd.'s net margin of --. Alibaba Health Information Technology Ltd.'s return on equity of 9.22% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ALBBYAlibaba Health Information Technology Ltd.-- -- $2.2B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About ALBBY or RGC?
Alibaba Health Information Technology Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Alibaba Health Information Technology Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Alibaba Health Information Technology Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ALBBYAlibaba Health Information Technology Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is ALBBY or RGC More Risky?
Alibaba Health Information Technology Ltd. has a beta of 1.029, which suggesting that the stock is 2.862% more volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALBBY or RGC?
Alibaba Health Information Technology Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alibaba Health Information Technology Ltd. pays -- of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALBBY or RGC?
Alibaba Health Information Technology Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Alibaba Health Information Technology Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Alibaba Health Information Technology Ltd.'s price-to-earnings ratio is 39.73x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alibaba Health Information Technology Ltd. is 2.32x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALBBYAlibaba Health Information Technology Ltd.2.32x 39.73x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
